Metrics as of 10/15/2026, 11:08 AM (Berlin time), refresh in progress.
KALA BIO Stock
KALA BIO, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Avi Minkowitz
- Employees
- 6
- Market cap
- $4 M
- IPO
- 20/07/2017
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is…
KALA BIO stock: price history
1D
-27.7%
1W
-47.8%
1M
-65.2%
6M
-98.1%
YTD
-99.3%
1Y
-99.8%
2Y
-99.9%
5Y
-100.0%
10Y
–
Next earnings date
Next earnings date
10/11/2026 (in 24 days)
Volatility around earnings
~9% weaker price swings than usual
Ask the agents about KALA BIO
Analyst assessment of KALA BIO
PRICE TARGET LOW
US$1.50
CONSENSUS
US$18.25
MEDIAN
US$18.25
PRICE TARGET HIGH
US$35.00
0
STRONG BUY
4
BUY
6
HOLD
1
SELL
0
STRONG SELL
11
TOTAL · Hold
As of: 30/09/2025
KALA BIO stock metrics
P/E
-0
P/B
0
EV/EBITDA
-0.39
RETURN ON EQUITY
-17.5%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
96.1%
FLOAT SHARES
18,588,345
AVG. DAILY VOLUME (30D)
2,690,049
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about KALA BIO stock
What does KALA BIO do?
KALA BIO, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Avi Minkowitz, the company employs around 6 people.
The IPO was on 20/07/2017; the stock trades on NASDAQ under the ticker KALA.
What do analysts say about KALA BIO stock?
11 analysts rate the stock, the consensus is Hold (as of 30/09/2025).
The average price target is US$18.25, ranging from US$1.50 to US$35.00, with a median of US$18.25.
This is an external assessment, not a statement by Market Jury.
When does KALA BIO report next?
The next earnings date is 10/11/2026.
Around past earnings, price swings were roughly -9% stronger than usual.
Does KALA BIO pay a dividend?
No, KALA BIO currently does not pay a dividend.
Which stocks are comparable to KALA BIO?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get KALA BIO stock analyzed?
Clicking "Analyze stock" lets five strategies assess KALA BIO against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.